Conflicts of Interest Taint UK Gov panel investigating SSRI

Wed, 19 Mar 2003

An article from the UK Guardian sheds light on how the credibility of an expert investigative government appointed committee is corrupted by financial conflicts of interest.

Mounting complaints from patients and the UK watchdog organization, Social Audit, coupled by clinical experts who have examined the evidence, patient records, and clinical trial reports, reveal the emergence of severe drug-induced adverse effects–such as withdrawal symptoms and suicidal behavior–in a significant number of patients taking antidepressants–in particular the widely prescribed, selective serotonin reuptake inhibitors (SSRIs).

In response to these complaints a representative of the British Medicine Control Agency (MCA) announced in Parliament that an “intensive review” was under way. MCA is the UK equivalent of the FDA. The Guardian reports, however, that the credibility of the panel selected to investigate the link between SSRIs and life-threatening adverse effects, is now at issue. Those chosen to investigate the evidence the panel, It appears that, like the FDA, the UK drug agency oversight is overly influenced by the drug industry.

Question is, did the MCA select pharmacology experts who are financially compromised by their ties to the drug industry because there are no psychiatrists in the UK who are not supported by drug companies? or, is the agency that appointed the panel itself under the influence of pharmaceutical company interests?

For further information about the SSRI controversy in Britain, and correspondence between MCA and Charles Medawar, who heads the UK grassroots watchdog organization, Social Audit, see: http://www.socialaudit.org.uk/43800068.htm and
http://www.socialaudit.org.uk/4641010.htm

~~~~~~~~~~~~~~~

The Guardian
http://www.guardian.co.uk/Print/0,3858,4626619,00.html

Drugs inquiry thrown into doubt over members’ links with manufacturers Drugs inquiry links to makers

Sarah Boseley, health editor Monday March 17, 2003

The credibility of a government inquiry intended to settle the controversy surrounding widely prescribed anti-depressant drugs was thrown into question yesterday by revelations that most of the members have shareholdings or other links to the manufacturers.

The “intensive review” of the side effects of Seroxat, Prozac and other antidepressants of the SSRI (selective serotonin reuptake inhibitor) class was announced in the House of Commons by health minister Hazel Blears in December last year. It was a response to mounting concern from large numbers of patients who say they have been unable to come off Seroxat because of severe withdrawal symptoms.

It is also looking at allegations that the SSRIs have caused a small number of people who were previously not in a severely depressed state to kill themselves. Last week a coroner in Wales called for Seroxat to be withdrawn pending an investigation after returning an open verdict on a retired headteacher who killed himself shortly after starting the drug.

But campaigners and patients say they are deeply unhappy with the membership of the review team, drawn from the committee on the safety of medicines, which is part of the Department of Health’s medicines control agency, and with one of the expert witnesses.

Two of the four CSM scientists, Michael Donaghy, a reader in clinical neurology from Oxford University, and David Nutt, professor of psychopharmacology at Bristol University, hold shares in GlaxoSmithKline, manufacturers of Seroxat. They have to leave the room when Seroxat is discussed, although they stay for debate on the SSRI drugs as a class.

Prof Nutt and the invited expert, David Baldwin, senior lecturer in psychiatry at Southampton University, jointly fronted the promotional press launch of Seroxat after it won a licence to be prescribed for social anxiety disorder and was popularly dubbed the “shyness pill”.

Charles Medawar, of the watchdog organisation Social Audit, is seeking a reference to the ombudsman over the composition of the review.

He is also unhappy with the choice of chairman. Angus Mackay, director of mental health services in Lomond and Argyle, Scotland, was one of the signatories to an influential paper produced by the CSM in 1996 which concluded that withdrawal symptoms from SSRIs are rare, “relatively mild and do not have features of a physical drug dependency syndrome”.

Mr Medawar said the review must be impartial and seen to be impartial. The Seroxat users group, which has 4,000 members who have experienced problems with the drug personally or through relatives, is equally concerned. “We’re not at all happy,” said Sarah Venn of the group.

Their Cardiff-based lawyer, Mark Harvey, said he was concerned that two of the review members had shareholdings in GSK. “The review could go two ways,” he said. “If it says the drug is beneficial, the share price goes up and you make a profit. If it says the drug is dreadful, the price goes down and you make a loss. I do not see any way at all that you can be expected to give an impartial judgment. This is absolutely unacceptable.”

Mr Harvey was also unhappy that the review has not undertaken to consider the first-hand evidence of patients on the side effects they say they have suffered – only the reports from their doctors will be considered – although it has invited representatives of the Seroxat users group to a meeting.

The medicines control agency and the committee on the safety of medicines have always maintained that it is sufficient for members to declare their interests in drug companies before meetings and to leave the room if they have personal interests such as shareholdings.

At the meeting of the review group on November 21, Prof Nutt and Dr Donaghy declared personal interests in GSK and left the room for two items on the agenda that dealt with Seroxat, although they remained for discussions on the SSRIs as a class of drug.

Dr Baldwin declared a personal interest in Lundbeck, manufacturers of the drug Citalopram. According to the minutes, however, he did not declare his connections with five other companies, including Seroxat manufacturers SmithKline Beecham, which is now GlaxoSmithKline.

Questioned by the Guardian, he said that although it was hard to remember the detail, he did declare participating in advisory boards for SmithKline Beecham, Bristol-Myers Squibb, Eli Lilly, Organon, and Pharmacia. His department had also been funded for studies by the same five companies and he had been paid by them for speaking at symposia to other doctors about the drugs. “I mentioned all this at the meeting,” he said.

A spokesman for the MCA said the minutes would not have omitted anything. “The minutes containing the declared interests would contain everything, including studies declared,” he said.

The MCA insists, however, that the system for preventing conflicts of interests works well. “All members of committees and associated working groups are professionals of the highest standing in their fields and there has never been any evidence that members have acted other than with the highest integrity,” it said.

Guardian Unlimited © Guardian Newspapers Limited 2003

FAIR USE NOTICE: This may contain copyrighted (© ) material the use of which has not always been specifically authorized by the copyright owner. Such material is made available to advance understanding of ecological, political, human rights, economic, democracy, scientific, moral, ethical, and social justice issues, etc. It is believed that this constitutes a ‘fair use’ of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, this material is distributed without profit to those who have expressed a prior general interest in receiving similar information for research and educational purposes. For more information go to: http://www.law.cornell.edu/uscode/17/107.shtml If you wish to use copyrighted material for purposes of your own that go beyond ‘fair use’, you must obtain permission from the copyright owner.